Chimeric Antigen Receptor-T Cell Therapy
10.3904/kjm.2022.97.4.229
- Author:
Ja Min BYUN
1
;
Sung-Soo YOON
Author Information
1. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
- Publication Type:16
- From:Korean Journal of Medicine
2022;97(4):229-237
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Chimeric antigen receptor (CAR) T-cell therapy constitutes a revolutionary advancement in personalized cancer treatment. During this treatment, a patient's own T cells are genetically engineered to express a synthetic receptor that binds a tumor antigen. CAR-T cells are then expanded for clinical use and infused back into the patient's body to attack cancer. CAR-T cells have produced remarkable clinical responses with B-cell malignancies. However, CAR-T cells therapy is not without problems. Barriers to effective CAR-T cells therapy include severe life-threatening toxicities and modest anti-tumor activity. In this review, we introduce the concept of CAR-T cells therapy, currently available CAR-T cells therapy options, and how to deal with adverse events.
